Pregnancy and childbirth were once listed as contraindications to SLE. Today, most patients with SLE can safely become pregnant and have children after their disease is controlled. In general. In the absence of significant organ damage, the disease has been stable for 1 year or more, and cytotoxic immunosuppressive drugs have been discontinued for 6 months. Pregnancy is possible when hormones are maintained only in low doses (≤10 mg/d). The risk of miscarriage, preterm delivery, stillbirth and induced deterioration of maternal disease are associated with the birth of a non-remitting SLE pregnancy. Pregnancy in patients with SLE should not be carried out when the disease is unstable. After pregnancy, both obstetricians and rheumatologists need to follow up. Prednisolone is inactivated when it passes through the placenta, but dexamethasone and betamethasone can cross the placental barrier and affect the fetus, so they should not be used; however, dexamethasone can be used to promote fetal lung maturation in the second trimester. Immunosuppressants such as cyclophosphamide and methotrexate are used from the first 3 months of pregnancy to the gestation period. It can affect fetal growth and development leading to malformation. For pregnant women with a history of habitual abortion and positive antiphospholipid antibodies, oral low-dose aspirin and/or low-dose low-molecular heparin anticoagulation is recommended to prevent miscarriage or stillbirth.